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 Midkine (MK) is one of a family of heparin-binding growth factors whose gene was identified 
in embrypnal carcinoma. MK messenger RNA (mRNA) is highly expressed in various tissues 
during the midgestation period of mouse embryogenesis, and it is considered to be involved in 
regulation of organogenesis. Increased MK mRNA and protein expression are exhibited in many 
human carcinomas such as gastric, pancreas, bile duct, colorectal, hepatocellular cancers as well 
as in Wilms' tumor and neuroblastoma. Serum level of MK is reportedly elevated in patients 
with esophageal cancer or neuroblastoma However, little is unknown about usefulness of 
determination of serum MK as a tumor marker in patients with digestive cancers. In the present 
study, we measured serum levels of MK in various digestive cancers and benign diseases, and 
evaluate its clinical significance as a tumor marker.  
 Serum levels of MK were measured by enzyme-linked immunosorbent assay (ELISA) using 
rabbit anti-human MK antibody as a first antibody, and biotinylated mouse anti-MK antibody as 
a second one in the sera from digestive malignant diseases (n=139) and benign diseases (n=87). 
The cut-off value of serum MK was set at 450pg/ml chiefly based on the ROC curve. The 
positive rate of MK in each cancer was as follows: 40% (14/35) in pancreatic cancer, 64% 
(23/36) in gastric cancer, 67% (16/24) in colorectal cancer, 38% (17/45) in hepatocellular cancer, 
and 71% (5/7) in bile duct cancer. Among patients with gastric or colorectal cancer, the positive 
rate of serum MK was relatively high and had no relation to the stage of cancer shown in Fig. 
High positivity of MK of gastric or colorectal cancer in stageⅠis worthy of notice. On the other 
hand, positivity of serum MK in benign digestive disease was as follows: 31% (5/16) in chronic 
hepatitis, 33% (4/12) in chronic pancreatitis, 16% 
 (2/12) in acute pancreatitis, and 67% (6/9) in     
cholangitis., indicating that false positivity is  
high in inflammatory diseases.                
 In conclusion , serum MK level increased in               
a variety of digestive cancers, especially in  
gastric and colorectal cancer. These results 
suggest that determination of serum MK  
may be useful as an aid in initial screening 
of gastrointestinal cancers, although false          Fig. Relationships between serum MK 
positivity is high in inflammatory diseases.           levels and tumor stage in gastric cancer  
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